drugset / Trial / NCT03965858
Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Depression
Phase 2
Completed
88 enrolled
Celon Pharma SA
National Center for Research and Development, Poland · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of the study is to determine the efficacy, safety and pharmacokinetics of inhaled Esketamine in participants with treatment-resistant depression (TRD) in the course of Major Depressive Disorder (MDD). The study is to determine the efficacy and dose response of three Esketamine doses, compared with placebo.
Timeline
- Start
- 2019-02-25
- Primary completion
- 2020-03-15
- Completion
- 2020-04-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Esketamine | Other / unclassified | — | Inhaled |